The data on the kappa AL amyloidosis group treated with anselamimab was presented by AstraZeneca at ASCO 2026.

AbbVie’s ADC has secured FDA clearance for an ultra-rare blood cancer while the agency has delayed its decision on ...

AstraZeneca (LSE:AZN) received US FDA approval for IMFINZI (durvalumab) with BCG therapy in BCG naïve, high risk non muscle invasive bladder cancer, based on positive Phase III data showing a ...

The FDA has delayed a decision on the approval of AstraZeneca’s camizestrant, deferring its ruling to review analyses filed ...

AstraZeneca has fired another volley in its bladder cancer competition with Merck’s Keytruda, with the FDA on Thursday ...

AstraZeneca and Daiichi Sankyo received FDA approval for Enhertu in early-stage HER2-positive breast cancer in both ...

AstraZeneca has shared data it believes can rescue anselamimab from a phase 3 failure, linking the drug candidate to a 62% improvement in survival among a prespecified subgroup of ...

AstraZeneca and Daiichi Sankyo have secured approval from the US Food and Drug Administration (FDA) for Datroway (datopotamab ...

Eli Lilly announced plans to acquire three early and mid-stage vaccine developers — Curevo, LimmaTech Biologics, and Vaccine Company — for a combined $3.8 billion. Blackstone Life Sciences is ...

Drugmaker had stalled large-scale projects in England but has now pledged investment at two sites, announced by Keir Starmer ...

An analyst said the decline in the stock was largely due to profit booking and did not indicate a reversal in the broader ...